Please login to the form below

Not currently logged in
Email:
Password:

Wim Goemaere appointed CFO at Bone Therapeutics

He joins from agricultural biotech firm Devgen

Wim Goemaere, Bone TherapeuticBone Therapeutics yesterday announced that Wim Goemaere is to join the company as chief financial officer.

Goemaere joins the biopharma company, which specialises in developing cell therapies for bone disorders, from Belgian agricultural biotech company Devgen, where he was also chief financial officer.

He spent five years in his role at Devgen, during which time he was involved in the takeover of the company by Syngenta for €403m.

Prior to this position, Goemaere was chief financial officer of Flanders Institute for Biotechnology, supporting the growth of the organisation into a leading research body. He also has experience at BP.

“His extensive experience of both the financial and biopharmaceutical sectors will be invaluable to the company as we progress to the next stage of our development,” commented Enrico Bastianelli, CEO of Bone Therapeutics.

This growth centres around the development of the company's lead product Preob, which is in phase III trials for the treatment of osteonecrosis and non-union fractures.

Bone Therapeutics is also developing an allogeneic bone cell therapy product called allob.

18th September 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics